Recent Updates — KNSA

Kiniksa Pharmaceuticals International reported third-quarter 2026 total revenue of $286.0 million, driven by a ~58% year-over-year increase in net product revenue for its ARCALYST franchise. The company posted net income of $47.3 million and raised its full-year 2026 ARCALYST net product revenue guidance to between $1.045 billion and $1.050 billion, up from the previous range of $980 million to $995 million. The biopharmaceutical company is developing and commercializing novel therapies for cardiovascular indications.

The Compensation Committee appointed Ross Moat as President and Chief Operating Officer effective October 17, 2026. He will report to Chairman and CEO Sanj K. Patel. His annual base salary is set at $700,000 with a target bonus of 60% starting January 1, 2027. Moat has been with the company since June 2019, most recently serving as EVP and COO overseeing commercial, clinical, regulatory, and manufacturing operations. Kiniksa Pharmaceuticals International operates in the biopharmaceutical industry.

Kiniksa Pharmaceuticals International, plc reported second quarter 2026 financial results, posting net product revenue of $243.6 million, a 55% increase from the prior year period. The company raised its full-year 2026 ARCALYST net product revenue guidance to $980–$995 million, up from the previous range of $930–$945 million. Net income for the quarter was $25.4 million, compared to $17.8 million in the same period last year. The firm also announced that its pivotal Phase 3 trial for KPL-387, PASTORALE, has begun enrolling and dosing patients for recurrent pericarditis. Kiniksa operates in the biopharmaceutical industry, developing and commercializing novel therapies for cardiovascular and inflammatory diseases.